Dr. John Leonard on Treatment Options in Follicular Lymphoma
John Leonard, MD, discusses the number of options doctors have to choose from when treating follicular lymphomas.
John Leonard, MD, medical oncologist, Weill Cornell Medicine and NewYork-Presbyterian Hospital, discusses the number of options doctors have to choose from when treating follicular lymphomas. Leonard says some of the more common and older options for these patients are the anti-CD20 antibody rituximab and bendamustine, with the latter being used especially if the patient had not previously received it in combination with rituximab.
Leonard says in addition to those treatments, the anti-body obinutuzumab has also been approved in patients with rituximab refractory relapsed follicular lymphoma. Data for idelalisib, a PI3 kinase inhibitor that can work in rituximab refractory patients, and RCHOP chemotherapy is another option, are also viable options, according to Leonard.
Examining the Non-Hodgkin Lymphoma Treatment Paradigm
July 15th 2022In season 3, episode 6 of Targeted Talks, Yazan Samhouri, MD, discusses the exciting new agents for the treatment of non-Hodgkin lymphoma, the clinical trials that support their use, and hopes for the future of treatment.
Listen
Timing of DLBCL Relapse Linked With Evolutionary Patterns
December 1st 2023A report suggests the cause behind different outcomes among patients with diffuse large B-cell lymphoma who relapse, highlighting that patients whose cancer relapses shortly after treatment tend to have worse responses to additional chemotherapy-based treatment.
Read More
Updated Data Show Efficacy of Tafasitamab/Lenalidomide in R/R DLBCL
November 28th 2023In the first article of a 2-part series, Hayder Saeed, MD, discusses the 5-year follow up data from the L-MIND study, which shows the continuing efficacy of tafasitamab and lenalidomide for patients with relapsed/refractory diffuse large B-cell lymphoma.
Read More
Connecting Heart Disease and Hematologic Malignancies
November 28th 2023A real-world analysis found that patients with acute coronary syndrome who were also diagnosed with a hematologic malignancy had worse survival outcomes, and patients with multiple myeloma were overrepresented in the population.
Read More
